Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea-Reference-Cited by-同舟云学术

Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea

Published:2023-06-19 Issue:1 Volume:18 Page:116-124
ISSN:1976-2283
Container-title:Gut and Liver
language:en
Short-container-title:Gut and Liver

Author:

Han Sojung¹^ORCID,Kim Do Young²^ORCID,Lim Ho Yeong³^ORCID,Yoon Jung-Hwan⁴^ORCID,Ryoo Baek-Yeol⁵^ORCID,Kim Yujeong⁶^ORCID,Kim Kookhee⁶^ORCID,Kim Bo Yeon⁶^ORCID,Yi So Young⁶^ORCID,Kim Dong-Sook⁶^ORCID,Cho Do-Yeon⁶^ORCID,Yu Jina⁶^ORCID,Kim Suhyun⁶^ORCID,Park Joong-Won⁷^ORCID

Affiliation:

1. Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji University College of Medicine, Uijeongbu, Korea

2. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

3. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

4. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

5. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

6. Health Insurance Review and Assessment, Wonju, Korea

7. Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea

Publisher

The Editorial Office of Gut and Liver

Subject

Gastroenterology,Hepatology

Link

https://pdf.medrang.co.kr/GNL/2024/018/GNL018-01-116.pdf

Reference29 articles.

1. Global cancer statistics, 2012

2. The Impact of Socioeconomic Status on Mortality in Patients with Hepatocellular Carcinoma: A Korean National Cohort Study

3. Management of hepatocellular carcinoma: An update

4. Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma

5. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma;Gut and Liver;2024-01-15